Ernexa Therapeutics (ERNA) Stock Soars 78% Following Q1 Earnings and Pipeline Update

Key Takeaways

• First-quarter 2026 net loss came in at $5.51M, an improvement from $8.20M during the same quarter of 2025.
• Loss per diluted share decreased substantially to $(6.95) compared to $(57.76) in the prior-year period.
• Cash reserves stood at $9.2M at quarter-end, supported by a $10.5M February capital raise.
• ERNA-101 demonstrated complete tumor elimination and 100% sustained survival in animal models when used alongside PD-1 checkpoint inhibitors.
• The biotech executed a 1-for-25 reverse split in May and registered a $50M shelf offering with an accompanying ATM facility for capital flexibility.

Shares of Ernexa Therapeutics (ERNA) climbed more than 78% on May 11 following the release of first-quarter 2026 financial results. The early-stage cell therapy developer showed significant progress in reducing its quarterly deficit while advancing its experimental treatment programs.

Ernexa Therapeutics Inc., ERNA

For the three months ending March 31, 2026, Ernexa recorded a net loss of $5.51 million, marking a considerable reduction from the $8.20 million deficit reported during the first quarter of 2025. This represents a year-over-year improvement of approximately $2.70 million.

The company’s diluted loss per share registered at $(6.95), demonstrating substantial improvement versus the $(57.76) recorded in the corresponding 2025 quarter. The prior-year metric reflects share counts before the company’s recent 1-for-25 reverse stock consolidation, which became effective on May 4, 2026.

Total operating expenditures for the reporting period reached $5.6 million. This figure encompasses $1.9 million allocated to research and development activities, $1.6 million in general and administrative costs, and a $2.0 million non-cash goodwill impairment.

The company closed the quarter with $9.2 million in available cash. This balance benefited from a February 2026 public equity offering that generated roughly $10.5 million in gross capital through the sale of common shares, pre-funded warrants, and milestone-linked warrants.

Company leadership acknowledged that the approximately $8.3 million in cash available as of April 30 is insufficient to meet anticipated operational requirements through the next twelve months.

To address this funding shortfall, Ernexa has registered a $50 million universal shelf offering and established an at-the-market equity distribution program. Through this ATM facility, the company anticipates access to as much as $9.2 million in additional capital.

Preclinical Data Highlights ERNA-101 Potential

On the development front, ERNA-101, Ernexa’s primary oncology asset, demonstrated the ability to slow tumor expansion in laboratory models. When administered in combination with PD-1 immune checkpoint blockade, the experimental therapy achieved complete tumor eradication and 100% durable survival in the reported preclinical experiments.

These findings originate from animal studies—human clinical validation remains ahead. Ernexa disclosed it has completed a preliminary meeting with the FDA regarding its Investigational New Drug application and intends to formally submit the IND later this year, with a Phase I investigator-initiated clinical study planned for the second half of 2026.

The organization is simultaneously progressing ERNA-201, an induced mesenchymal stem cell therapy engineered to secrete interleukin-10 for treating autoimmune disorders. Management is actively exploring collaborative agreements and grant opportunities to fund continued advancement.

International Growth and Regulatory Positioning

Beyond its scientific milestones, Ernexa gained acceptance into a trade acceleration initiative focused on facilitating commercial entry into the Japanese market.

The reverse stock consolidation, which resulted in 1,166,333 outstanding common shares as recorded on May 8, 2026, serves partly as a compliance strategy. Management expects the action will enable Ernexa to satisfy Nasdaq minimum bid price requirements.

As of the March 31, 2026 quarter-end, Ernexa had 1,166,333 shares of common stock outstanding on a retroactively adjusted basis following the reverse split.

The post Ernexa Therapeutics (ERNA) Stock Soars 78% Following Q1 Earnings and Pipeline Update appeared first on Blockonomi.